Not Quite FDARA Add-Ons: Right-To-Try, Patient Experience, Opioid Measures Also Clear US Senate
Executive Summary
Senate passage of the FDA user fee package without amendments was enabled by unanimous consent votes on controversial right-to-try legislation that is toned down from its initial version, as well as two other bills.
You may also be interested in...
Right-To-Try Bill Heads To White House, Putting Firms In Driver's Seat
Proponent says companies ready to use new expanded access pathway that US FDA will have essentially no involvement in.
Right-To-Try Legislation Must Change Language To Narrow Spectrum Of Patients, Gottlieb Says
US FDA commissioner tells House hearing that the Senate's legislation in its current form could undermine the intent of addressing terminally ill patients.
FDA Policy Says Right-to-Try Talks Are Between Providers, Sponsors
New internal policy says the US agency cannot force a drug maker to supply an unapproved drug to a patient for expanded access and that the provider must seek company approval to provide the product.